



## State-of-the-Art and Novel Approaches in Molecular and Translational Medicine in Europe

Guest Editor:

**Dr. Vasileios Tzounakas**

Department of Biochemistry,  
School of Medicine, University of  
Patras, Patras, Greece

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editor

Dear Colleagues,

The rapid advancement of technology has led to the establishment of high throughput and state-of-the-art techniques that benefit biomedicine research. There is a growing interest in unraveling the mechanistic basis of pathophysiological backgrounds, identifying accurate and easy-to-detect biomarkers, and finding novel promising therapies through the use of omics technologies, bioinformatics analyses, and other technological breakthroughs.

In this Special Issue, European experts in the field of biomedicine are invited to present the progress of translational medicine in our continent through the use of novel or state-of-the-art approaches in the fields of molecular, cellular, and biochemical medicine. These approaches may include high throughput techniques, *in vitro* and *in vivo* models of disease/physiology, bioinformatic tools and novel therapeutics, as well as unique approaches for studying biomedical issues.

Dr. Vasileios Tzounakas  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)